➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Harvard Business School
Merck
Dow
Moodys

Last Updated: November 26, 2020

DrugPatentWatch Database Preview

Omalizumab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for omalizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
NovartisPhase 1
Beth Israel Deaconess Medical CenterPhase 1
University of VirginiaPhase 4

See all omalizumab clinical trials

Recent Litigation for omalizumab

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2017-12-20

See all omalizumab litigation

Pharmacology for omalizumab
Mechanism of ActionIgE-directed Antibody Interactions
Physiological EffectDecreased IgE Activity

Patent Text Search: US Patents for omalizumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for omalizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
C/GB06/006 United Kingdom   Start Trial PRODUCT NAME: OMALIZUMAB AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/05/319/001 20051024; UK EU/1/05/319/002 20051024
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Harvard Business School
Mallinckrodt
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.